Overall survival (OS) in contemporary randomized clinical trials (RCT) in advanced breast cancer (ABC)

被引：0
|
作者：
Katz, A. [1 ,2 ,3 ]
Saad, E. D. [1 ,2 ,3 ]
Buyse, M. E. [1 ,2 ,3 ]
机构：
[1] Sirio Libanes Hosp, Sao Paulo, Brazil
[2] Dendrix Res, Sao Paulo, Brazil
[3] Int Inst Drug Dev, Louvain, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1002
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Post-Progression Survival (PPS) and Overall Survival (OS) According to Treatment Type in Contemporary Phase III Trials in Advanced Breast Cancer (ABC)
    Saad, E. D.
    Katz, A.
    Machado, K. K.
    Buyse, M.
    [J]. CANCER RESEARCH, 2009, 69 (24) : 804S - 804S
  • [2] Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials
    Saad, Everardo D.
    Katz, Artur
    Buyse, Marc
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) : 1958 - 1962
  • [3] Evaluation of overall survival (OS), progression-free survival (PFS), or time to progression (TTP) in systematic review of randomized clinical trials (RCT) in patients with metastatic breast cancer (MBC)
    Mukonje, Terence
    Santana-Davila, Rafael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Subgroup Analyses in Contemporary Phase III Trials in Advanced Breast Cancer (ABC).
    Calabrich, A.
    Katz, A.
    Saad, E. D.
    [J]. CANCER RESEARCH, 2009, 69 (24) : 627S - 628S
  • [5] Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit?
    Kuemmel, S.
    Jackisch, C.
    Mueller, V.
    Schneeweiss, A.
    Klawitter, S.
    Lux, M. P.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [6] Surrogate endpoints for overall survival (OS) in advanced pancreatic cancer (APC): Analysis of randomized clinical trials (RCTs) exploring gemcitabine (G)-based combinations
    Milella, M.
    Bria, E.
    Carlini, P.
    Cuppone, F.
    Gelibter, A.
    Nistico, C.
    Ruggeri, E. M.
    Terzoli, E.
    Cognetti, F.
    Giannarelli, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Modeling tumor measurement data to predict overall survival (OS) in cancer clinical trials
    Ou, Fang-Shu
    Tang, Jun
    An, Ming-Wen
    Mandrekar, Sumithra J.
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2021, 23
  • [8] RELATIONSHIP BETWEEN PROGRESSION-FREE (PFS) AND OVERALL SURVIVAL (OS) IN I-LINE RANDOMIZED CLINICAL TRIALS (RCT) FOR ADVANCED RENAL CELL CARCINOMA (RCC): CORRELATION AND POWER ANALYSIS
    Bria, E.
    Massari, F.
    Maines, F.
    Bonomi, M.
    Porta, C.
    Bracarda, S.
    Cognetti, F.
    Giannarelli, D.
    Tortora, G.
    Milella, M.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 273 - 273
  • [9] Influence of clinical trial participation with regard to overall survival (OS) and progression-free survival (PFS) for patients with advanced breast cancer
    Kiechle, M.
    Simstich, N. S.
    Schwarz-Boeger, U. R.
    Paepke, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Effect of the quality of the methodology on the relationship between progression-free survival (PFS) and overall survival (OS) in advanced colorectal cancer clinical trials.
    Garcia-Albeniz, X.
    Carrera, G.
    Feliu, J.
    Aparicio, J.
    Torres, F.
    Maurel, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345